What makes the matter more difficult is that science has not yet achieved an effective treatment for the disease despite strenuous efforts in this area, hence the recent announcement of approval United States Food and Drug Administration Of a new drug that would slow cognitive decline in the early stages of the disease, a revolution in the world of medicine.
What you should know about the new medicine
- The drug is named after "I like it" (This group)Also known as the Lucanib (lecanemab).
- poses "Licanim" Its active ingredient is administered to patients intravenously once every two weeks.
- Preliminary data from the Liquimbe study, released in September, showed the drug slowed cognitive decline in Alzheimer’s patients by 27 percent over an 18-month period..
- The property is developed by my company "Esay" Japanese, f"Biogenic" American.
How does it work?
- The drug targets protein stores "amyloid".
- plaques "amyloid" They form around the neurons of Alzheimer’s patients and, in the long run, destroy them, causing memory loss.
Side effects
- The United States Food and Drug Administration has revealed that there is "Side effects" Negativity appeared during the experiments.
- The administration has warned of amyloid-associated abnormalities, which can lead to temporary swelling in areas of the brain that usually goes away with time.
- The swelling may be accompanied by small patches of bleeding, inside or on the surface of the brain.
- Some people may experience symptoms such as headache, confusion, dizziness, vision changes, nausea, and seizures.
- Intravenous reactions may also occur, with flu-like symptoms, nausea, vomiting, and changes in blood pressure.
Alzheimer’s patients and their doctors will have to decide whether these problems are worth enduring versus the drug’s benefits, which could potentially amount to slowing the disease for months..
price
- agency "Esay" He explained that he valued his property at $26,500 a year.
- Analysts of "Wall Street" They expected the price of the property to be around $20,000 a year, as predicted by the firm’s analyst "William Blair"Miles Minter, at the end of last year, was priced closer to $28,000.
Controversy over real estate leave
- Recall that the US Food and Drug Administration has developed "Licanumab" Fast-track approval, for people with early stages of a degenerative brain disease.
- The approval came a few days after the report for CongressIn it, he sharply criticized the administration for giving the green light to another drug to treat Alzheimer’s patients "Aduelmus" (Aduelmus).
- In turn, the administration said that "Lekembe and Adohelm represent a major breakthrough in the ongoing battle to effectively treat Alzheimer’s disease".
“>
Prepare Alzheimers One of the diseases that most affects human life and exerts enormous psychological pressure on those around the patient, who gradually watch him “leave” and his personality traits disappear little by little.
What makes the matter more difficult is that science has not yet achieved an effective treatment for the disease despite strenuous efforts in this area, hence the recent announcement of approval United States Food and Drug Administration Of a new drug that would slow cognitive decline in the early stages of the disease, a revolution in the world of medicine.
What you should know about the new medicine
- The property is namedI like it“ (This group)Also known as the Lucanib (lecanemab).
- Licanib is its active ingredient and is given to patients intravenously once every two weeks.
- Preliminary data from the Liquimbe study, released in September, showed the drug slowed cognitive decline in Alzheimer’s patients by 27 percent over an 18-month period..
- The property is developed by my company.Esay“Japanese” andBiogenicAmerican.
How does it work?
- The drug targets protein stores.amyloid“.
- Amyloid plaques form around the neurons of Alzheimer’s patients, destroying them over time, causing memory loss.
Side effects
- The US Food and Drug Administration has revealed that there were negative “side effects” that appeared during the experiments.
- The administration has warned of amyloid-associated abnormalities, which can lead to temporary swelling in areas of the brain that usually goes away with time.
- The swelling may be accompanied by small patches of bleeding, inside or on the surface of the brain.
- Some people may experience symptoms such as headache, confusion, dizziness, vision changes, nausea, and seizures.
- Intravenous reactions may also occur, with flu-like symptoms, nausea, vomiting, and changes in blood pressure.
Alzheimer’s patients and their doctors will have to decide whether these problems are worth enduring versus the drug’s benefits, which could potentially amount to slowing the disease for months..
price
- The company, Esay, said it valued its property at $26,500 a year.
- “Wall Street” analysts had forecast the property price to be around $20,000 a year, while “William Blair” company analyst Miles Minter was forecasting a price closer to $20,000 a year late last year. 28,000.
Controversy over real estate leave
- The U.S. Food and Drug Administration has put licanumab on the fast track to approval for people with the early stages of the disease, which affects the brain.
- The approval came a few days after the report for CongressIn it, he sharply criticized the administration for giving the green light to another drug to treat Alzheimer’s patients, which is “Aduelmus” (Aduelmus).
- In turn, the administration said, “Lekembe and Adohelm represent a major advance in the ongoing battle to effectively treat Alzheimer’s disease.”“.
